Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new treatment for Primary Open-Angle Glaucoma POAG using the Hexiris Microinvasive Scleral Trephine MIST system, a medical device designed to reduce intraocular pressure IOP in adults aged 40 years or older whose glaucoma is not controlled by topical medications. This multicenter, open-label, single-arm study focuses on safety and performance, treating only one eye per participant. The study includes an initial phase with five patients treated in an operating room and a subsequent phase with twenty patients treated in a clinic setting under a slit lamp. Participants will receive treatment with the Hexiris MIST device combined with a subconjunctival injection of mitomycin C. The first five treatments occur in the operating room, after which safety data will determine if the remaining patients are treated in the clinic. The procedure is performed under topical anesthesia using a sterile technique. Postoperative care involves topical antibiotics and steroids. Follow-up visits are scheduled at the day after treatment, then at 1 week, and 1, 2, 3, 6, 9, and 12 months. During follow-up, ophthalmologists will examine the treated eye and measure intraocular pressure along with other assessments such as bleb morphology, corneal thickness, and medication use. Researchers will monitor for safety events and device performance throughout the one-year study period. The primary outcome is the change in intraocular pressure from baseline to 6 months, with several secondary outcomes tracked up to 12 months post-treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called ONL1204 in people aged 55 and older who have geographic atrophy GA related to age-related macular degeneration AMD. GA associated with AMD is a leading cause of vision loss and blindness globally, linked to aging and other risk factors. This phase 2 study aims to understand how different doses and treatment schedules of ONL1204 affect this condition. Participants will receive one of several treatments ONL1204 injections at two dose levels 100 or 200 micrograms every 12 weeks, ONL1204 200 micrograms every 24 weeks, sham injections every 12 or 24 weeks, or monthly injections of avacincaptad pegol. All injections are given into the eye intravitreal. This randomized, double-masked trial compares these different groups over a period of 48 weeks. During the study, participants will have regular visits for eye exams, imaging, and vision tests to monitor their condition and treatment effects. Researchers will track safety and efficacy outcomes throughout the 48 weeks. Participants must meet specific vision and eye health criteria to join, and safety monitoring will continue throughout the treatment period to ensure participant well-being.